Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Genprex Inc. GNPX

Genprex Inc is a clinical-stage gene therapy company. It is focused on developing life-changing therapies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who have limited treatment options. It works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies to provide novel treatment approaches...


Recent & Breaking News (NDAQ:GNPX)

Genprex Signs Exclusive License to Additional Diabetes Technology with the University of Pittsburgh

PR Newswire January 5, 2023

Genprex Announces Selection of Preclinical Data for Oral Presentation at 16th International Conference on Advanced Technologies & Treatments for Diabetes

PR Newswire January 4, 2023

Genprex Strengthens Diabetes Gene Therapy Program with License of Additional Technology from University of Pittsburgh

PR Newswire December 15, 2022

Genprex Receives Safety Review Committee Approval to Proceed to Final Cohort in Acclaim-1 Phase 1 Dose Escalation Trial of REQORSA® in Combination with Tagrisso® in Advanced Non-Small Cell Lung Cancer

PR Newswire December 14, 2022

Genprex to Present at Upcoming December Investor Conference

PR Newswire December 2, 2022

Genprex to Present at Upcoming October Investor and Industry Conferences

PR Newswire October 7, 2022

Genprex to Present at Upcoming September Investor Conference

PR Newswire September 8, 2022

Genprex Announces U.S. Patent for REQORSA(TM) Immunogene Therapy in Combination with Immune Checkpoint Inhibitors to Treat Cancers

PR Newswire August 16, 2022

Genprex Announces Safety Review Committee Approves Dose Escalation in Acclaim-1 Phase 1/2 Trial of REQORSA(TM) in Combination with Tagrisso® in Non-Small Cell Lung Cancer

PR Newswire August 15, 2022

Genprex to Participate in Next Generation Lipid-Based Nanoparticles Delivery Summit

PR Newswire July 13, 2022

Genprex to Present at Upcoming June Investor Conferences

PR Newswire June 2, 2022

Genprex to Present at Upcoming Investor Conference in May 2022

PR Newswire May 19, 2022

Genprex's Chief Medical Officer to Be Featured as an Expert Panelist at the 33rd Annual Cancer Progress Conference

PR Newswire May 9, 2022

Genprex Issues Shareholder Letter and Provides 2022 Corporate Update

PR Newswire May 5, 2022

Genprex to Participate in Upcoming Investor and Industry Conferences in April 2022

PR Newswire April 18, 2022

Genprex Announces the Opening for Enrollment of its Phase 1/2 Acclaim-2 Clinical Trial of REQORSA(TM) Immunogene Therapy in Combination With Keytruda® to Treat Non-Small Cell Lung Cancer

Business Wire March 31, 2022

Genprex to Participate in Upcoming Investor Conference in March

Business Wire March 23, 2022

Genprex Announces First Patient Dosed in Phase 1/2 Acclaim-1 Clinical Trial of REQORSA(TM) Immunogene Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer

Business Wire March 2, 2022

Genprex to Present at Upcoming Investor Conferences Highlighting its Gene Therapies for Cancer and Diabetes

Business Wire February 9, 2022

Preclinical Data Show Potential for Use of Genprex's ONCOPREX® Nanoparticle Delivery System in Treating Colon Cancer

Business Wire January 27, 2022